Igm Monoclonal And Nervous System Disorders
Mouse Anti Human Macrophage (Tissue And Proliferative Disorders) Monoclonal Antibody |
|||
| DMABT-52185MH | Creative Diagnostics | 0.5 ml | 1226.4 EUR |
Human IgG antibody Laboratories manufactures the igm monoclonal and nervous system disorders reagents distributed by Genprice. The Igm Monoclonal And Nervous System Disorders reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact igm monoclonal. Other Igm products are available in stock. Specificity: Igm Category: Monoclonal Group: And Nervous
Neural Dissociation System 2 (Neurons, Neurons and glial,Retina), Mouse and Rat |
||
| CHI Scientific | ea | Ask for price |
Nervous necrosis virus |
||
| Bioingentech | PCR-V261-48R | 485 EUR |
Nervous necrosis virus |
||
| Bioingentech | PCR-V261-96R | 685 EUR |
Nervous necrosis virus |
||
| Bioingentech | Oneq-V261-100R | 1028 EUR |
Nervous necrosis virus |
||
| Bioingentech | Oneq-V261-150R | 1438 EUR |
Nervous necrosis virus |
||
| Bioingentech | Oneq-V261-50R | 728 EUR |
Adrenal Dissociation System 3 (Adrenocortical), Mouse and Rat |
||
| CHI Scientific | ea | Ask for price |
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF568 conjugate, 0.1mg/mL |
|||
| BNC683793-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF568 conjugate, 0.1mg/mL |
|||
| BNC683793-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF594 conjugate, 0.1mg/mL |
|||
| BNC943792-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF594 conjugate, 0.1mg/mL |
|||
| BNC943792-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF594 conjugate, 0.1mg/mL |
|||
| BNC943793-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF594 conjugate, 0.1mg/mL |
|||
| BNC943793-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF640R conjugate, 0.1mg/mL |
|||
| BNC403792-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF640R conjugate, 0.1mg/mL |
|||
| BNC403792-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF640R conjugate, 0.1mg/mL |
|||
| BNC403793-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF640R conjugate, 0.1mg/mL |
|||
| BNC403793-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF405S conjugate, 0.1mg/mL |
|||
| BNC043792-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF405S conjugate, 0.1mg/mL |
|||
| BNC043792-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF405S conjugate, 0.1mg/mL |
|||
| BNC043793-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF405S conjugate, 0.1mg/mL |
|||
| BNC043793-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF488A conjugate, 0.1mg/mL |
|||
| BNC883792-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF488A conjugate, 0.1mg/mL |
|||
| BNC883792-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF488A conjugate, 0.1mg/mL |
|||
| BNC883793-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||